Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
PLoS One. 2010 May 25;5(5):e10817. doi: 10.1371/journal.pone.0010817.
Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26. However, neither these assays nor other laboratory tests are widely accepted for the diagnosis or prognosis of CFS. This study sought to determine if NKCC or DPPIV/CD26 have diagnostic accuracy for CFS.
METHODS/RESULTS: Subjects included female and male CFS cases and healthy controls. NK cell function was measured with a bioassay, using K562 cells and (51)Cr release. Lymphocyte associated DPPIV/CD26 was assayed by qualitative and quantitative flow cytometry. Serum DPPIV/CD26 was measured by ELISA. Analysis by receiver operating characteristic (ROC) curve assessed biomarker potential. Cytotoxic function of NK cells for 176 CFS subjects was significantly lower than in the 230 controls. According to ROC analysis, NKCC was a good predictor of CFS status. There was no significant difference in NK cell counts between cases and controls. Percent CD2+ lymphocytes (T cells and NK cells) positive for DPPIV/C26 was elevated in CFS cases, but there was a decrease in the number of molecules (rMol) of DPPIV/C26 expressed on T cells and NK cells and a decrease in the soluble form of the enzyme in serum. Analyses by ROC curves indicated that all three measurements of DPPIV/CD26 demonstrated potential as biomarkers for CFS. None of the DPPIV/C26 assays were significantly correlated with NKCC.
By ROC analysis, NKCC and three methods of measuring DPPIV/C26 examined in this study had potential as biomarkers for CFS. Of these, NKCC, %CD2+CD26+ lymphocytes and rMol CD26/CD2+ lymphocyte, required flow cytometry, fresh blood and access to a high complexity laboratory. Soluble DPPIV/C26 in serum is done with a standard ELISA assay, or with other soluble factors in a multiplex type of ELISA. Dipeptidyl peptidase IV on lymphocytes or in serum was not predictive of NKCC suggesting that these should be considered as non-redundant biomarkers. Abnormalities in DPPIV/CD26 and in NK cell function have particular relevance to the possible role of infection in the initiation and/or the persistence of CFS.
我们实验室和其他实验室的慢性疲劳综合征(CFS)研究表明,自然杀伤细胞(NK)细胞的细胞毒性降低,并且表达激活标志物二肽基肽酶 IV(DPPIV)的淋巴细胞比例升高,DPPIV 也称为 CD26。然而,这些检测方法和其他实验室检测方法都没有被广泛接受用于 CFS 的诊断或预后。本研究旨在确定 NK 细胞或 DPPIV/CD26 是否对 CFS 具有诊断准确性。
方法/结果:研究对象包括女性和男性 CFS 病例和健康对照。使用 K562 细胞和(51)Cr 释放,通过生物测定法测量 NK 细胞功能。通过定性和定量流式细胞术检测淋巴细胞相关的 DPPIV/CD26。通过 ELISA 法测量血清 DPPIV/CD26。通过接收者操作特征(ROC)曲线分析评估生物标志物的潜力。对 176 名 CFS 患者的 NK 细胞的细胞毒性功能进行了分析,结果表明其明显低于 230 名对照组。根据 ROC 分析,NKCC 是 CFS 状态的良好预测指标。病例和对照组之间的 NK 细胞计数没有显著差异。CFS 病例中 CD2+淋巴细胞(T 细胞和 NK 细胞)阳性的 DPPIV/C26 百分比升高,但 T 细胞和 NK 细胞上表达的 DPPIV/C26 分子(rMol)数量减少,并且酶的可溶性形式在血清中减少。ROC 曲线分析表明,DPPIV/CD26 的所有三种测量方法均具有作为 CFS 生物标志物的潜力。DPPIV/C26 的所有检测均与 NKCC 无显著相关性。
通过 ROC 分析,本研究中检查的 NKCC 和三种 DPPIV/CD26 测量方法均具有作为 CFS 生物标志物的潜力。在这些方法中,NKCC、%CD2+CD26+淋巴细胞和 rMol CD26/CD2+淋巴细胞需要流式细胞术、新鲜血液和进入高复杂性实验室。血清中的可溶性 DPPIV/C26 可以使用标准 ELISA 测定法进行检测,或者使用其他可溶性因子在多重 ELISA 类型中进行检测。淋巴细胞或血清中的 DPPIV/CD26 与 NKCC 无预测关系,表明它们应被视为非冗余生物标志物。DPPIV/CD26 和 NK 细胞功能的异常与感染在 CFS 的起始和/或持续中可能起作用特别相关。